Psychedelic drug developer Compass Pathways is preparing to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression (TRD), after reporting positive ...
Shares in psychedelic drug developer Compass Pathways are sliding today after it announced that it will slash its headcount by 30% and focus all its efforts on its treatment-resistant depression (TRD) ...
Rocket Pro adds Pro Purchase Power, offering 40 bps more with Compass buyer agents, and launches Jupiter loan origination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results